Oxurion Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687 for Treatment of DME

Source: Oxurion

Oxurion announced the enrollment of the first patient in a phase 1 open-label, multicenter, dose escalation study evaluating the safety of a single intravitreal injection of THR-687 for the treatment of patients with diabetic macula edema (DME).

THR-687 is a novel pan-RGD integrin antagonist currently being developed as a potential treatment for patients with diabetic eye disease. Preclinical studies have demonstrated THR-687’s role in targeting multiple aspects of retinal vascular disease such as vessel leakage, inflammation, and neovascularization.

This phase 1 study (THR-687-001 – NCT03666923) will primarily assess the safety of a single intravitreal injection of escalating dose levels of THR-687 in patients with DME. A maximum of 18 patients will be enrolled.

“We are very excited about the progress we have made in advancing THR-687 (pan-RGD integrin antagonist) into the clinic,” Patrik De Haes, MD, CEO of Oxurion, said in a company news release. “This is an important step in the clinical development of THR-687 and in establishing the safety profile of this pan integrin antagonist in patients with DME.”

This trial initiation follows the recent start of the phase 1 clinical trial with THR-149 (PKal inhibitor), and the initiation of a phase 2 with THR-317 (anti-PlGF) in combination with ranibizumab (Lucentis) in April, both for patients with DME. Our portfolio of comprehensive drug candidates addresses the clear unmet medical need for improved treatment options for this fast-growing diabetic eye disease market.”

Related Content